What are the recommended reporting requirements and treatment protocol for a newly diagnosed active tuberculosis case, including contact notification?

Reporting and Treatment Protocol for Active Tuberculosis

All newly diagnosed active TB cases must be reported to the local public health department within 1 week of diagnosis, with immediate initiation of a 4-drug regimen (isoniazid + rifampin + pyrazinamide + ethambutol or streptomycin) for 6 months total duration, while simultaneously conducting contact investigations for all exposed individuals. 1

Immediate Reporting Requirements

Report 100% of active TB cases to your local public health department within 7 days of diagnosis 1. This is non-negotiable and serves critical functions:

• Enables contact tracing and source case investigations to identify other infectious cases in the community
• Allows public health monitoring of treatment adherence
• Facilitates identification and treatment of infected contacts
• Permits surveillance to track TB control efforts 1

Report suspected cases immediately - don't wait for culture confirmation. Report based on clinical diagnosis or presence of acid-fast bacilli in specimens 1.

Initial Diagnostic Workup

Before starting treatment, obtain 3 sputum cultures for mycobacteria and drug susceptibility testing in 90% of adult patients 1. For children under 10 years who cannot produce sputum, use early morning gastric aspirates as an alternative 1.

Test all TB patients for HIV - aim for 80% to have HIV status determined within 2 months of TB diagnosis 1. This is critical because:

• 14% of US TB patients also have AIDS (up to 58% in some areas) 1
• HIV-positive patients may need modified treatment regimens if protease inhibitors are required
• Concurrent HIV treatment may accelerate TB resolution 1

Treatment Protocol

Standard Regimen (Drug-Susceptible TB)

Start isoniazid + rifampin + pyrazinamide + ethambutol (or streptomycin) immediately in geographic areas where ≥4% of TB isolates are resistant to isoniazid 1. This 4-drug regimen should be initiated in 90% of patients.

Total duration: 6 months 1

• All 4 drugs for first 2 months
• Isoniazid + rifampin continued throughout entire 6-month course
• Only miliary, meningeal, or bone/joint TB requires longer therapy 1

Directly Observed Therapy (DOT)

All patients should receive DOT - directly observed medication ingestion by a responsible person 1. Communities using DOT show decreased drug-resistant TB and relapse rates. Clinicians are poor at predicting adherence, so universal DOT is recommended rather than selective application 1.

Infection Control During Treatment

Place all smear-positive pulmonary or laryngeal TB patients in respiratory isolation until they become non-infectious 1. Keep 90% of smear-positive patients isolated until sputum smear converts to negative 1.

Contact Investigation and Management

Contact tracing is mandatory and should begin immediately upon case identification 2. Priority hierarchy for contact evaluation:

High Priority Contacts (Require Full Evaluation)

• Children aged <5 years (most susceptible to invasive, fatal TB)
• HIV-infected individuals
• Immunocompromised persons (organ transplant recipients, TNF-α antagonist users, chronic prednisone >15mg/day)
• Close contacts with frequent, prolonged exposure 2

Contact Testing Protocol

For children <5 years and immunocompromised contacts:

• Immediate medical evaluation including chest radiograph
• Tuberculin skin test (TST) with 5mm cutoff for positive result
• If initial TST <5mm and <8 weeks since last exposure: start window-period prophylaxis after excluding active disease
• Repeat TST at 8-10 weeks post-exposure
• If second test negative: discontinue treatment
• If second test positive: complete full latent TB treatment course 2

For HIV-infected contacts specifically:

• Even if TST negative at >8 weeks post-exposure, complete full latent TB treatment course after excluding active disease 2

DOT Priority for Contacts on Preventive Therapy

When resources are limited, prioritize DOT for:

1. Contacts aged <5 years
2. HIV-infected or immunocompromised contacts
3. Contacts with TST conversion (negative to positive)
4. Contacts with social/behavioral barriers (substance use, mental illness, unstable housing, unemployment) 2

Target 85% treatment completion rate for infected contacts 2.

Monitoring During Treatment

At 3 months: Reevaluate all smear-positive patients. If still smear-positive, perform culture and susceptibility testing within 1 month to assess for non-adherence or drug resistance 1. This should occur in 90% of applicable patients.

Treatment failure: If suspected, add ≥2 new anti-TB agents immediately in 100% of cases 1.

Common Pitfalls to Avoid

• Don't wait for culture confirmation to report - report on clinical suspicion
• Don't skip the 4th drug (ethambutol/streptomycin) in areas with ≥4% isoniazid resistance
• Don't assume you can predict which patients will adhere - use DOT universally
• Don't delay contact investigation - begin immediately, especially for vulnerable populations
• Don't forget HIV testing - it fundamentally changes management approach